The role of topotecan in the treatment of advanced cervical cancer (Q35226248)

7 August 2017

1 reference

title

The role of topotecan in the treatment of advanced cervical cancer (English)

1 reference

7 August 2017

main subject

cervix uterine cancer

1 reference

James V Fiorica

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

7 August 2017

1 reference

7 August 2017

1 reference

7 August 2017

issue

3 Pt 2

1 reference

7 August 2017

page(s)

S16-21

1 reference

Update on the treatment of cervical and uterine carcinoma: focus on topotecan

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Global cancer statistics in the year 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

The role of chemotherapy in invasive cancer of the cervix uteri: current standards and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Cancer of the Uterine Cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group stud

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Topotecan for recurrent cervical cancer after platinum-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Prospective assessment of quality of life of female cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Interaction of ionizing radiation with topotecan in two human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Phase I study of topotecan and radiation therapy in advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Weekly topotecan in the management of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2803%2900465-7

7 January 2021

10.1016/S0090-8258(03)00465-7

Identifiers

DOI

1 reference

7 August 2017

1 reference